BioSpace News Archive

Meitheal Pharmaceuticals, Inc. announced recent progress for its generic injectables portfolio, underscoring the Company’s commitment to serve as a sustainable partner for generics development in the U.S.

AffyImmune Therapeutics, Inc announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.

Nascent Biotech, Inc. and HypoSpray Pharma announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab.

Catheter Precision, Inc., a US based medical device company focused on electrophysiology products, is honored to be sponsor a session at the upcoming Monaco USA Arrhythmia Course taking place March 21-23 in Monaco.

Coya Therapeutics, Inc. announces its financial results for the year ended December 31, 2023.

Connect Biopharma Holdings Limited today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m. ET.

IceCure Medical Ltd. today announced positive topline results from the Company’s ICE3 study, the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors.

US BioTek Laboratories (“US BioTek”), a Clinical Laboratory Improvement Amendments (CLIA) and CAP accredited laboratory, announces the acquisition of Dallas, TX-based RealTime Laboratories (“RealTime”), a pioneer in the field of mycotoxin testing.

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Enable Biosciences Clinical Reference Laboratory in South San Francisco, California, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.